Evidence map›Paper›PMID 41003978›Full record

ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2025

Molecular epidemiology of global carbapenemase-producing Serratia spp. (2015-2017).

Gisele Peirano, Yasufumi Matsumura, Johann D D Pitout

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. First Report of a Carbapenem-ResistantInfection and drug resistance · 2026
    Article
  2. Microorganisms · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Gisele PeiranoAlberta Precision Laboratories, Calgary, AB, Canada.
Yasufumi MatsumuraKyoto University Graduate School of Medicine, Kyoto, Japan.
Johann D D PitoutAlberta Precision Laboratories, Calgary, AB, Canada. jpitout@ucalgary.ca.

Funding

NIH HHS 10028552
6 · The paper itself

Abstract

Limited information is available regarding the global molecular epidemiology of Serratia spp. with carbapenemases. We characterized carbapenemase-producing Serratia spp. (n = 56) using short read whole genome sequencing (WGS) obtained from global surveillance programs (2015-17). KPC (54%), VIM (16%) and NDM (14%) were the most common carbapenemases, followed by OXA-48 (10%), IMP-8 (four %), GES-5 (two %). The population was heterogenous, consisting of seven species and thirty-two clones. Serratia sarumanii (32%), Serratia nevei (23%), Serratia marcescens sensu stricto (20%) were the principal species. S. sarumanii contained three dominant clones: ST795 with bla

Indexed as

Bacterial Proteinsbeta-LactamasesSerratiaSerratia InfectionsAnti-Bacterial AgentsGenome, BacterialGlobal HealthHumansMicrobial Sensitivity TestsMolecular EpidemiologyWhole Genome SequencingAnti-Bacterial AgentsBacterial Proteinsbeta-LactamasescarbapenemaseCarbapenemase-producing Serratia spp.Global genomic epidemiology

Identifiers

PMID41003978

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.